Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley J, Sanchez Y, Penrod J, Goldman D, et al. Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.1301

Reference

Title
Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley J, Sanchez Y, Penrod J, Goldman D, et al.
Volume & Issue
Volume 31, Issue 4
Pages
683-690
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Over the next 10 years, the number of cancer survivors in the U.S. is predicted to grow from 14.5 million to nearly 19 million (9.3 million men and 9.6 million…  
  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
  • From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical…  
  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • Following the current path, the lung cancer incidence rate will increase by 34% between 2003 and 2023. If an alternative path is taken, there will be 18.4% (92,000) fewer lung…